SABCS 2022 | Olaparib + durvalumab as a chemotherapy-free maintenance strategy in platinum treated advanced TNBC

Sarah L. Sammons, MD, Dana-Farber Cancer Institute, Boston, MA, shares the results of the Phase II DORA (NCT03167619) trial, exploring maintenance olaparib with or without durvalumab in advanced triple negative breast cancer (aTNBC). The primary endpoint was progression-free survival (PFS). Secondary endpoints were disease control rate (DCR), clinical benefit rate (CBR), and overall survival (OS). At a median follow-up of 9.8 months, the median PFS was 3.95 months with oloparib monotherapy and 6.1 months with olaparib plus durvalumab. CBR was 39.1% and 36.4% in with olparaib versus olaparib plus durvalumab, respectively. DCR was 52.2% and 68.2% with olparaib versus olaparib plus durvalumab, respectively. No new safety signals were resported. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.